Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAMASTE study of namilumab in axial spondyloarthritis
2018-000176-15Phase 2Completed
- Sponsor
- Izana Bioscience
- Start
- Jul 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in axial spondyloarthritis (axSpA) comparing Namilumab with Placebo (2 arms). Primary endpoint: ASAS20 response at week 12. Started Jul 2018; status: completed.
02
Drugs
namilumab
03
Conditions
axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on 2018-000176-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000176-15.